ROIVW (Roivant Sciences) Return-on-Tangible-Asset: 22.17% (As of Mar. 2026)


ROIVW Roivant Sciences Ltd ROIVW
51 GF Score
Price $2.75
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Return-on-Tangible-Asset?

Roivant Sciences ROIVW -3.85% 51 Return-on-Tangible-Asset is 22.17% as of Mar. 2026. GuruFocus rates ROIVW with a GF Score™ of 51/100. The stock has 7 warning signs investors should review. Among 1,412 Biotechnology companies, Roivant Sciences ranks better than 74.93% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Roivant Sciences's annualized Net Income for the quarter that ended in Mar. 2026 was $1,211.98 Mil. Roivant Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was $5,467.03 Mil. Therefore, Roivant Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 22.17%.

The historical rank and industry rank for Roivant Sciences's Return-on-Tangible-Asset or its related term are showing as below:

ROIVW' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -41.78   Med: -18.32   Max: 91.87
Current: -5.66

During the past 6 years, Roivant Sciences's highest Return-on-Tangible-Asset was 91.87%. The lowest was -41.78%. And the median was -18.32%.

ROIVW's Return-on-Tangible-Asset is ranked better than
74.93% of 1412 companies
in the Biotechnology industry
Industry Median: -35.475 vs ROIVW: -5.66

Roivant Sciences  (NAS:ROIVW) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Roivant Sciences Return-on-Tangible-Asset Related Terms


Roivant Sciences Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Return-on-Tangible-Asset Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Return-on-Tangible-Asset
Get a 7-Day Free Trial -32.67 -41.78 91.87 -2.72 -5.38

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.71 -17.07 -9.00 -20.68 22.17

ROIVW vs RPRX, BNTX, INCY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Roivant Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Return-on-Tangible-Asset falls into.


ROIVW
51GF Score
Roivant Sciences Ltd ROIVW
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Return-on-Tangible-Asset Calculation

Roivant Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-299.771/( (5436.94+5708.687)/ 2 )
=-299.771/5572.8135
=-5.38 %

Roivant Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1211.976/( (5225.368+5708.687)/ 2 )
=1211.976/5467.0275
=22.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of 22.17% mean?
Roivant Sciences (ROIVW) has a Return-on-Tangible-Asset of 22.17% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Roivant Sciences and its competitors. According to the industry distribution chart, Roivant Sciences ranks #354 out of 1412 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Roivant Sciences' Return-on-Tangible-Asset too high?
Roivant Sciences' current Return-on-Tangible-Asset is 22.17%. Based on the distribution chart, Roivant Sciences ranks #354 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Roivant Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Return-on-Tangible-Asset compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #354 out of 1412 companies for Return-on-Tangible-Asset. This puts Roivant Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Return-on-Tangible-Asset is 22.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Roivant Sciences (ROIVW) has a current Return-on-Tangible-Asset of 22.17%. The current Return-on-Tangible-Asset is 22.17%. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Roivant Sciences (ROIVW), the current Return-on-Tangible-Asset is 22.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score

Get the complete analysis for ROIVW

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price